DLL3 and small cell lung carcinoma: The clinical applicability of this approach has shown promising clinical response in small cell lung cancer (SCLC), where anti-CD3 x anti-delta-like ligand 3 (anti-DLL3) bispecific antibody tarlatamab was given FDA approval for platinum-treatment refractory SCLC [46].